key: cord-317552-hyyw6eln
authors: Huette, Pierre; Beyls, Christophe; Guilbart, Mathieu; Coquet, Alexandre; Berna, Pascal; Haye, Guillaume; Roger, Pierre-Alexandre; Besserve, Patricia; Bernasinski, Michael; Dupont, Hervé; Abou-Arab, Osama; Mahjoub, Yazine
title: Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: outcome and time-course of clinical and biological parameters
date: 2020-06-01
journal: Can J Anaesth
DOI: 10.1007/s12630-020-01727-z
sha: 
doc_id: 317552
cord_uid: hyyw6eln

nan

The place of extracorporeal membrane oxygenation (ECMO) therapy in the coronavirus disease 2019 (COVID-19) outbreak is undefined. 1 Our tertiary hospital is situated in Picardy (northern France), one of the areas most affected by the outbreak in France. We report a prospective caseseries that describes the clinical course of patients with COVID-19 with respiratory failure requiring veno-venous ECMO between March 2020 and April 2020.

After ethical approval, we prospectively collected data on consecutive COVID-19 patients (confirmed with reverse transcription polymerase chain reaction testing) admitted to our referral centre for ECMO therapy. Demographic, biological, and clinical data were collected during ECMO therapy. Data on outcomes were reported. Fourteen patients were eligible for ECMO during this period; two of them died in peripheral centres during ECMO cannulation (one patient was in refractory septic shock and one patient had a massive pulmonary embolism Ten (83%) patients were weaned from ECMO and two patients died under ECMO. Duration of ECMO therapy was 12 [9-22] days. Nine patients (75%) were weaned from mechanical ventilation. Overall, eight patients (67%) were discharged from the ICU and four (33%) died (Figure) . Lung-protective ventilation was maintained during ECMO. Duration of mechanical ventilation was 25 [19-30] days and ten (83%) patients developed ventilator associated pneumonia (VAP). All patients received heparin treatment for an anti-Xa level target of 0.2-0.3 UIÁmL -1 . Thrombotic events occurred in 11 (92%) patients: deep vein thrombosis (four patients), renal replacement therapy (RRT) circuit clotting (two patients), complete clotting of the ECMO circuit (three patients), and pulmonary embolism (two patients). Eleven (92%) patients had Kidney Disease: Improvement of Global Outcomes 2 or 3 classification of acute kidney injury (AKI) and eight (67%) required RRT (eTable 3 as ESM). In this case-series of patients with COVID-19-related respiratory failure, we found a high rate of ECMOweaning. Complications such as AKI, thrombosis, and VAP occurred frequently. A high risk of thrombosis for COVID-19 patients under ECMO has been suggested previously. 3 At the initiation of ECMO, patients had low lymphocyte counts that increased progressively until weaning, in accordance with previous reports showing that most severe COVID-19 cases had persistently low lymphocyte counts. 4 In our experience, a reduction in fibrinogen correlates with improvements in oxygenation. Decreasing fibrinogen levels may be a marker for improvement in the coagulopathy and a reduction in disease severity, with improvement in oxygenation. 5 Studies with a larger sample size are needed to draw formal conclusions about the benefit of ECMO therapy for COVID-19-related respiratory failure.

Disclosures None.

Editorial responsibility This submission was handled by Dr. Sangeeta Mehta, Associate Editor, Canadian Journal of Anesthesia. 

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

Covid-19 does not lead to a ''typical'' acute respiratory distress syndrome

Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis

Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations